Navigation Links
QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline
Date:7/24/2014

QIAGEN's Personalized Healthcare Program Leader. "Building on a broad portfolio of molecular diagnostics for blood cancers, QIAGEN continues to partner with clinical researchers at pharmaceutical companies and academic centers to extend the benefits of personalized healthcare. Because several Pharma companies are developing potential anti-cancer drugs targeting the SF3B1 gene, this biomarker also holds potential for co-development as a companion diagnostic."

QIAGEN licensed the SF3B1 biomarker in an ongoing expansion of the oncohematology offering for clinical research and diagnostics. Three additional spliceosome biomarkers implicated in various blood cancers and targeting variants in the U2AF35 (U2AF1), ZRSR2 and SFRS2 genes are also part of the license agreement. They are included in QIAGEN's GeneRead DNAseq Leukemia V2 gene panel for next-generation sequencing (NGS), which has been launched earlier this month together with 13 other new cancer gene panels that are compatible with any NGS sequencer and customizable to include other genes or gene regions of clinical or biological interest. The GeneRead technology provides the most cost-effective and time-efficient approach for target enrichment of assay panels for NGS. The panels use as little as 10 nanograms of starting DNA material per pool, require only three hours to enrich for targets and substantially reduce the time to go from isolated DNA sample to sequencing-ready libraries. They are compatible for use with FFPE samples, do not require specialized instruments, and achieve industry leading coverage (>96% of coding regions), specificity (>90% of reads on target) and uniformity (>90% of bases covered by at least 20% of the mean coverage depth)."

With more than 60 tests already offered worldwide for the diagnosis, prognosis and follow-up of patients with blood cancer, QIAGEN is a clear leader in research and clinical diagnosis of blood cancers. Earlier this year, QIAGEN licensed th
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
2. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
3. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
4. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
5. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
6. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
7. QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities
8. Exosome Diagnostics and QIAGEN Partner to Launch Comprehensive Line of Biofluid Nucleic Acid Kits to Address Limitations of Tissue Biopsy in Clinical Research Market
9. Financial Results, Appointments, Earnings Conferences, and Partnerships - Research Report on New Oriental Education & Technology, Acacia Research, DeVry, Capella Education, and Qiagen NV
10. QIAGEN Offers Clinical Labs Early Access to New Ingenuity Solution for Streamlined Interpretation of Patient Sequencing Data
11. Maverix Biomics Forms Strategic Co-Marketing Alliance with QIAGEN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... t:slim® and t:flex™ Insulin Pumps, today announced the pricing ... its common stock at a price to the public ... from this offering are expected to be $56.3 million, ... offering expenses payable by Tandem. All of the shares ...
(Date:2/26/2015)... , Feb. 26, 2015  Mail-service and ... consumers, employers and government health plans $23.3 ... released by the Pharmaceutical Care Management Association (PCMA). ... drugs offers one of the easiest ways to ... Mark Merritt . "Policymakers should resist efforts ...
(Date:2/26/2015)... , Feb. 26, 2015  BD Life Sciences, a ... BDX ), a leading global medical ... focused on enabling high-resolution biology, today announced that ... for highly multiplexed cell isolation and single-cell gene ... BD,s powerful BD FACS™ single-cell sorting instrumentation and ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 3
... YORK, Dec. 15, 2011  New York University and the ... they have appointed Theodore (Ted) Rappaport, 51, to lead ... Rappaport, currently the William and Bettye ... at Austin (UTA), is a leading educator and entrepreneur ...
... 15, 2011  Today, the Consumer Healthcare Products Association (CHPA), announced ... Five Moms campaign to raise awareness of ... of two teenage boys and a high school math teacher ... the dangers of substance abuse. Millions of ...
Cached Medicine Technology:Wireless Engineering Pioneer Joins NYU-Poly and NYU 2Wireless Engineering Pioneer Joins NYU-Poly and NYU 3Wireless Engineering Pioneer Joins NYU-Poly and NYU 4CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 3
(Date:2/27/2015)... February 27, 2015 Qualis Health, ... organizations, has been named a finalist in the ... recognition of outstanding commitment toward continuous improvement in ... in reducing hospital readmission rates through its Communities ... are honored to receive this national recognition, which ...
(Date:2/27/2015)... February 27, 2015 Jvion announced ... is collaborating with the Atlanta-based software company through ... of Jvion’s advanced predictive capabilities suite within the ... that identifies and prevents financial and clinical losses ... predictions that help prevent patient deterioration and suffering, ...
(Date:2/27/2015)... WI (PRWEB) February 27, 2015 UAS ... Adult Cubes, at Natural Products Expo West, March 6 ... are very excited to release the hands down best ... cream taste with an extra zing of Vitamin C. ... Cubes, winner of the NutrAward 2014, Delicious Living’s Supplement ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Aligned ... five local neighborhood health centers, officially welcomes Dr. ... Medicine based in Aligned Modern Health’s Lincoln Square, ... graduated from the National University of Health Sciences ... Award. She has completed post-graduate coursework in ...
(Date:2/27/2015)... 2015 The purpose of the Rouche ... to explore the current use of 3D printing in ... contribute to the Survey about 3D Printing please go ... use among large and small companies from a wide ... recent PwC and Manufacturing Institute survey of 3D Printing ...
Breaking Medicine News(10 mins):Health News:Qualis Health Named Award Finalist for Care Transitions Work 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 3Health News:UAS LifeSciences to Launch UP4 Adult Cubes at Expo West 2Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 2Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 3Health News:Survey of Texas Manufacturers, Technology, Life Sciences and Innovation Companies Reveals Broad, Varied Interest and Skills Shortage in 3D Printing Applications Says NAU 2Health News:Survey of Texas Manufacturers, Technology, Life Sciences and Innovation Companies Reveals Broad, Varied Interest and Skills Shortage in 3D Printing Applications Says NAU 3
... procedures, survey shows , FRIDAY, July 31 (HealthDay News) -- ... visited a plastic surgeon for a "makeover" -- a ... around her lips and at the corners of her mouth. ... might lose her competitive edge in a tightening job market. ...
... , , WASHINGTON, July 31 ... Tobacco-Free Kids: , , (Logo: ... Council has taken an important step to protect the District,s kids and ... tax by 50 cents to $2.50 per pack - the seventh highest ...
... Fla., July 31 Sanofi-aventis US announced yesterday that the FDA ... in the USA. It offers results that last for years. Dr ... the product while abroad. It was approved in Europe(CE) for over ... global pharmaceutical company. The FDA approval is based on results from ...
... Md., July 31 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, today,announced ... results,on Monday, August 10, 2009, before the market opens. Management ... 10, 2009 to discuss financial results. , ...
... , , ... Administration (FDA) today approved the first and only antipsychotic for ... were approved for the acute treatment of schizoaffective disorder either ... INVEGA(R) was approved in 2006 for the treatment of schizophrenia. ...
... , Campaign Officially Launches ... months of college students and others wrestling with the creative challenge ... for its nationwide sign design contest. The victors are Kelsey Hazzard, ... law school this fall at the University of Virginia, and Christina ...
Cached Medicine News:Health News:Plastic Surgeons Stay Busy in Recession 2Health News:Plastic Surgeons Stay Busy in Recession 3Health News:District of Columbia Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:Chindex International, Inc. to Report First Quarter Fiscal 2010 Financial Results 2Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 2Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 3Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 4Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 5Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 6Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 7Health News:CandleInTheWindow.org Announces $1000 Scholarship Prize Winners 2
... is a standard gelling temperature, high gel ... than 1,000 bp. This Genetic Technology Grade™ ... DNA electrophoresis. DNA recovered from SeaKem GTG ... ligated. SeaKem GTG Agarose is extensively performance ...
... is recommended for separations of DNA fragments ... that are easy to handle, and remains ... minimizes the risk of cracking or breaking. ... (GQT) products with similar sieving properties, is ...
The WADiana Compact is a fully automated immuno-haematology analyser, easy to use with maximum security including clot detection and ensuring no contamination....
... PK7200 works on patented microplate agglutination ... testing system for donor ABO/Rh testing. PK7200 ... syphilis and cytomegalovirus antibody detection. The Automated ... along with the proven reliability that for ...
Medicine Products: